PKI-402

ArtNr	S2739-1000
Hersteller	Selleckchem
CAS-Nr.	1173204-81-3
Menge	1 g
Quantity options	10 mg 1 g 10 g 200 mg 5 mg 50 mg 5 g
Kategorie	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Breast Cancer
Typ	Inhibitors
Specific against	other
Smiles	CCN1C2=C(C(=NC(=N2)C3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)C(=O)N5CCN(CC5)C)N6CCOCC6)N=N1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1173204-81-3'
Similar products	PKI-402
Lieferbar
Manufacturer - Targets	PI3K, MTOR
Storage Conditions	2 years -80 in solvent
Molecular Weight	570, 65
Administration	Administered by i.v. route
Animal Models	Female nude mice injected subcutaneously with MDA-361, U87MG, or A549 cells
Cell lines	MDA-MB-361, MDA-MB-468, T47D, MCF7, BT474, HT29, HCT116, DLD1, U87MG, H157, NCI-H460, A549, NCI-H1975, NCI-H1650, NCIH2170, KB, 786-0, A498, MIA-PaCa-2, and PC3
Concentrations	Dissolved in DMSO, final concentrations ca.3 uM
Dosages	ca.100 mg/kg/day
Formulation	Dissolved in 0.5% methylcellulose and 0.4% polysorbate 80 (Tween-80)
IC50	2 nM, 2 nM, 2 nM, 2 nM, 2 nM, 2 nM
In vitro	Equivalent to the IC50 for wild-type PI3Kalpha, PKI-402 inhibits E545K and H1047R PI3Kalpha mutants with IC50 of 3 nM. In a panel of 236 human protein kinases, PKI-402 only displays inhibitory activity against C-Raf and B-Raf with IC50 of 7 uM, and displays little activity against all other kinases with IC50 of > 10 uM. PKI-402 inhibits the growth of human tumor cell lines with IC50 of 6-349 nM. Consistently, PKI-402 inhibits phosphorylation of PI3K and mTOR effector proteins, particularly phosphorylated Akt (p-Akt) at T308 and S473 with IC50 of <10 nM and <30 nM, respectively. PKI-402 inhibits both p70S6K and 4EBP1 phosphorylation with IC50 of <10 nM. PKI-402 inhibits Akt phosphorylation of PRAS40 at T246 with IC50 of <30 nM, and inhibits Akt phosphorylation of ENOS at S1177 and GSK3alpha/GSK3beta at S9/S21 with IC50 of <10 nM. In MDAMB-361, a breast tumor line with mutant PI3K-alpha (E545K) and elevated levels of Her2 receptor, PKI-402 treatment induces cleaved poly(ADP-ribose) polymerase (PARP), a marker for apoptosis. Less than 10% of MDAMB-361 cells exposed to PKI-402 at 0.3 uM (or higher) for 24 hours remain viable. [1]
In vivo	Single dose of PKI-402 (100 mg/kg) suppresses Akt phosphorylation (at T308) and induces cleaved PARP in MDA-MB-361 tumors. In normal tissue (heart and lung), PKI-402 (100 mg/kg) has minimal effect on p-Akt, with no detectable cleaved PARP. Consistently, PKI-402 at 100 mg/kg (daily for 5 days, one round) reduces initial tumor volume of 260 mm3 to 129 mm3 and prevents tumor regrowth for 70 days in MDA-MB-361. PKI-402 significantly inhibits the growth of A549 tumors in nude mice at 25 mg/kg and 50 mg/kg. PKI-402 at 100 mg/kg (daily for 5 days, one round) causes significant (P < 0.01) reduction in tumor growth of U87MG. [1]
Incubation Time	72 hours
Kinase Assay	Fluorescence polarization format assay, Enzyme assays are done in fluorescent polarization (FP) format, adapted from the Echelon K-1100 PI3K FP assay kit protocol. Assay reaction buffer is 20 mM Hepes, pH 7.5, 2 mM MgCl2, 0.05% CHAPS, and 0.01% betaME. Assay STOP/detection buffer is 100 mM Hepes, pH 7.5, 4 mM EDTA, 0.05% CHAPS. FP assays are run in Nunc 384-well black polypropylene fluor plates. The FP reaction is run in 20 uL of reaction buffer containing 20 uM PIP2, 25 uM ATP, and >4% DMSO. The reaction is run for 30 minutes at room temp. The reaction is stopped with 20 uL of STOP/detection buffer containing 10 nM probe and 40 nM GST-GRP. Assay plates are incubated for 2 hours, and fluorescence polarization is measured in a Perkin-Elmer Envision plate reader with TAMRA-FP filters.
Method	Cell growth inhibition is determined using the CellTiter 96 Aqueous nonradioactive cell proliferation assay. This homogeneous colorimetric method determined the number of viable cells in proliferation assays. The assay is carried out in 96-well format, with cell number numbers per well being adjusted on the basis of growth characteristics of the various cell lines used. Assay end point data are quantitated after 72 hours of PKI-402 exposure using a Victor2 V (Wallac) model 1420 multilabel HTS counter.
Solubility (25C)	DMSO 0.4 mg/mL, Water <1 mg/mL, Ethanol <1 mg/mL
Information	PKI-402 is a potent dual pan-PI3K/mTOR inhibitor targeting PI3Kα/β/γ/δ and mTOR with IC50 of 2 nM/7 nM/16 nM/14 nM and 3 nM, respectively; also potent to PI3Kα mutants E545K and H1047R.
Chemical Name	1-(4-(3-ethyl-7-morpholino-3H-[1, 2, 3]triazolo[4, 5-d]pyrimidin-5-yl)phenyl)-3-(4-(1-methylpiperazine-4-carbonyl)phenyl)urea

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

S2739-1000-datasheet.pdf

S2739-1000-safety-datasheet.pdf